Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenol SCHEMBL28648858 | 0.87 | CA12 (0.37) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL6136532 | 0.86 | AKR1C3 (0.44) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL30747 | 0.84 | ALDH1A1 (0.36) | CA12CA1CA2GLACA3 | |
| SCHEMBL554467 | 0.82 | — | — | |
| SCHEMBL554468 | 0.82 | — | — | |
| Methylamine SCHEMBL4365894 | 0.80 | GRIK1 (0.37) | TDP1CYP3A4CYP1A2ALDH1A1GRIK1 | |
| Iodide SCHEMBL32659710 | 0.80 | GRIK1 (0.37) | TDP1CYP3A4CYP1A2ALDH1A1GRIK1 | |
| Bromide SCHEMBL29726693 | 0.80 | GRIK1 (0.37) | TDP1CYP3A4CYP1A2ALDH1A1GRIK1 | |
| Hydrochloric Acid SCHEMBL1534217 | 0.80 | GRIK1 (0.37) | TDP1CYP3A4CYP1A2ALDH1A1GRIK1 | |
| Bromide SCHEMBL29726696 | 0.80 | GRIK1 (0.37) | TDP1CYP3A4CYP1A2ALDH1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116878-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-04-11 | — | — | US | disclosed |
| US-20240067636-A1 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2024-02-29 | — | — | US | disclosed |
| EP-4302834-A2 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-3484856-B1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11702411-B2 | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11661401-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-05-30 | — | — | US | disclosed |
| EP-3980128-A1 | SOLID FORMS OF {6-[(2-AMINO-3-CHLOROPYRIDIN-4-YL)SULFANYL]-3-[(3S,4S)-4-AMINO-3-METHYL-2-OXA-8-AZASPIRO[4.5]DECAN-8-YL]-5-METHYLPYRAZIN-2-YL}METHANOL, AN SHP2 INHIBITOR | Revolution Medicines, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| US-11220501-B2 | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a SHP2 inhibitor | Revolution Medicines, Inc. (US) | 2022-01-11 | — | — | US | disclosed |
| US-20210253574-A1 | SOLID FORMS OF {6-[(2-AMINO-3-CHLOROPYRIDIN-4-YL)SULFANYL]-3-[(3S,4S)-4-AMINO-3-METHYL-2-OXA-8-AZASPIRO[4.5]DECAN-8-YL]-5-METHYLPYRAZIN-2-YL}METHANOL, AN SHP2 INHIBITOR | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-08-19 | — | — | US | disclosed |
| US-20210101870-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-04-08 | — | — | US | disclosed |
| EP-3484856-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2019-05-22 | — | — | EP | disclosed |
| WO-2019075265-A1 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2019-04-18 | — | — | WO | disclosed |
| WO-2018013597-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2018-01-18 | — | — | WO | disclosed |
| EP-1904459-A1 | NEW CRYSTAL FORMS OF 4-[6-METHOXY-7-(3-PIPERIDIN-1-YL-PROPOXY)QUINAZOLIN-4-YL]PIPERAZINE-1-CARBOXYLIC ACID(4-ISOPROPOXYPHENYL)-AMIDE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007012042-A1 | NEW CRYSTAL FORMS OF 4-[6-METHOXY-7-(3-PIPERIDIN-1-YL-PROPOXY)QUINAZOLIN-4-YL]PIPERAZINE-1-CARBOXYLIC ACID(4-ISOPROPOXYPHENYL)-AMIDE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| EP-1272483-A2 | OXINDOLE INHIBITORS OF FACTOR Xa | MILLENIUM PHARMACEUTICALS, INC. (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001072708-A2 | OXINDOLE INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2001-10-04 | — | — | WO | disclosed |
| EP-0946164-A4 | INTEGRIN ANTAGONISTS | MERCK & CO INC (US) | 2000-08-23 | — | — | EP | disclosed |
| EP-0946164-A1 | INTEGRIN ANTAGONISTS | Merck & Co., Inc. (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998018461-A1 | INTEGRIN ANTAGONISTS | MERCK & CO., INC. (US) | 1998-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116878-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN2, PTPN22 | CA12 3923/4885CA1 4492/4885CA2 1830/4885 |
| US-11661401-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN22, PTPN2 | CA12 3280/4885CA1 3889/4885CA2 2097/4885 |
| US-20240067636-A1 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN2, PTPN1 | CA12 4036/4885CA1 4293/4885CA2 1853/4885 |
| US-20210101870-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN22, PTPN2 | CA12 3280/4885CA1 3889/4885CA2 2097/4885 |
| US-11702411-B2 | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors | PTPN5, PTPN2, PTPN1 | CA12 4036/4885CA1 4293/4885CA2 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.